JNJ 61178104

Drug Profile

JNJ 61178104

Alternative Names: JNJ-61178104

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 20 May 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Belgium (SC)
  • 20 May 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Belgium (IV)
  • 03 May 2016 Janssen Research & Development plans a phase I trial in Healthy volunteers in Belgium (IV and SC) (NCT02758392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top